Dr. Art Kamm, a former vice president at Glaxo who was involved in the development of Zantac, has joined Salix Pharmaceuticals as its acting head of research and development.

The company announced the hiring of Kamm, who has managed his own drug development company and acted as a consultant since 1991, on Tuesday.

Salix (Nasdaq: SLXP) also reported a $24.7 million loss, or $1.21 per share, for 2002. Sales of its drug COLAZAL, an anti-inflammatory drug for the treatment of ulcerative colitis, increased to $33.5 million, up from $14.1 million the previous year. COLAZAL is the first drug Salix has taken to market.

The company projected 2003 sales to hit $50 million but also forecast that losses would continue, predicting a $1.20 per share loss. Salix ended 2002 with $55.7 million in cash and investments.

Kamm has been tasked to evaluate other drugs and strategies at Salix, the company said in a statement.

Salix: www.salix.com